Such inhibitors can serve as research tools in the investigation of leukemia- and Noonan syndrome-associated SHP-2 mutants that have lost the ability to form the N-SH2 – PTP interface characteristic of the self-inhibited wild-type SHP-2. This evidence concerns the gene PTPN11 and Noonan syndrome.